Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector.
To optimize findings at dynamic gadolinium-enhanced hepatic magnetic resonance imaging in the hepatic arterial phase, a timing examination was performed after injection of a 0.5-mL timing bolus of gadopentetate dimeglumine. In the experimental group (n = 28), power injection was used and the imaging delay was determined in each patient on the basis of the results of the timing examination. In the control group (n = 28), hand injection and a fixed 20-second imaging delay were used. Arterial-phase examinations (defined as relative liver enhancement of not more than 30% of peak parenchymal enhancement) were successful in 26 (93%) experimental group patients and in 17 (61%) control group patients.
Earls
J P
JP
Department of Radiology, New York University Medical Center, New York, NY 10016, USA.
Rofsky
N M
NM
DeCorato
D R
DR
Krinsky
G A
GA
Weinreb
J C
JC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media; D004338:Drug Combinations; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006499:Hepatic Artery / Q000473:pathology*; D006801:Humans; D007267:Injections / Q000295:instrumentation*; D008099:Liver / Q000473:pathology*; D008102:Liver Circulation; D008107:Liver Diseases / Q000175:diagnosis* / Q000503:physiopathology; D008113:Liver Neoplasms / Q000098:blood supply / Q000175:diagnosis; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid / Q000031:analogs & derivatives*; D011169:Portal Vein / Q000473:pathology
D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA